Iovance Biotherapeutics Inc’s filing revealed that its Director Maynard Ryan D unloaded Company’s shares for reported $0.5 million on Nov 12 ’24. In the deal valued at $10.06 per share,50,000 shares were sold. As a result of this transaction, Maynard Ryan D now holds 7,500 shares worth roughly $13425.0.
Then, Maynard Ryan D bought 50,000 shares, generating $503,104 in total proceeds.
Truist downgraded its Iovance Biotherapeutics Inc [IOVA] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Citizens JMP’s analysts, who decreased its forecast for the stock in early May from “a Mkt outperform” to “a Mkt perform”. UBS began covering IOVA with “Buy” recommendation on October 24, 2024. Piper Sandler revised its rating on July 29, 2024. It rated IOVA as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of IOVA
On Tuesday, Iovance Biotherapeutics Inc [NASDAQ:IOVA] saw its stock fall -7.25% to $1.79. Over the last five days, the stock has lost -42.26%. Iovance Biotherapeutics Inc shares have fallen nearly -75.81% since the year began. Nevertheless, the stocks have fallen -86.69% over the past one year. While a 52-week high of $12.51 was reached on 01/02/25, a 52-week low of $1.65 was recorded on 05/09/25. SMA at 50 days reached $3.3336, while 200 days put it at $7.2676.
Levels Of Support And Resistance For IOVA Stock
The 24-hour chart illustrates a support level at 1.6800, which if violated will result in even more drops to 1.5700. On the upside, there is a resistance level at 1.9400. A further resistance level may holdings at 2.0900. The Relative Strength Index (RSI) on the 14-day chart is 26.91, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.2360, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.27%. Stochastics %K at 8.33% indicates the stock is a buying.
The most recent change occurred on November 20, 2023 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $12 price target.
